Information Provided By: 
Fly News Breaks for October 20, 2015
RHHBY
Oct 20, 2015 | 07:42 EDT
Cowen downgrade Roche to Market Perform from Outperform as they see risks to the company's strategy, most notably its IO/IO combination therapy. The firm, which is also more cautious on Roche's IO/chemo approach ahead of the Avastin expiration at the end of the decade, lowered its price target to $35 from $42 on the shares.
News For RHHBY From the Last 2 Days
RHHBY
Apr 25, 2024 | 11:44 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
